

**Vermont Vaccine Purchasing Program
Assessment Calculation Worksheet**

Column →	A	B	C	D	E	F	G
	CHILDREN			ADULTS			
Line ↓	Prior	2018		Prior	2018		Comments
A. Preliminary Vaccine Cost Estimates							
01.	14,966,755	13,772,656		1,934,562	3,233,711		Estimated costs of vaccines (sheets e & f)
02.	1,497	1,377	0.01%	29,018	16,169	0.50%	Provision for vaccine utilization increase
03.	359,238	361,568	3.50%	17,918	56,873	3.50%	Provision for vaccine cost increase (% is annual) ¹
04.	15,327,490	14,135,601		1,981,498	3,306,753		Est. vaccines costs(w/ utilization & price adjustments.)
05.	-8,477,222	-7,998,850		-338,378	-380,110		Estimated VFC Award & 317 federal grant
06.	0	0		0	0		Other
07.	6,850,268	6,136,751		1,643,120	2,926,643		Estimated VVPP vaccine costs
08.	171,257	227,060	3.70%	41,078	108,286	3.70%	VDH administrative fee
09.	793,475	0		263,085	0		CDC Advance Funding Amortization (ended in 2017)
10.	7,815,000	6,363,811		1,947,283	3,034,929		Total vaccine and VDH administrative costs
B. Assessable Covered Lives Estimates							
11.	57,990	60,130		360,433	350,832		Assessable covered lives (sheet c)
12.	870	0	0.00%	5,406	1,737	0.50%	Leakage (unknown insurer, out of reach entity, etc.)
13.	57,120	60,130		355,027	349,095		Assessable lives actually paying
C. Financial Carry Forwards							
14.	674,169	604,594		113,293	78,160		Vaccine fund carryforward (sheet d.)
15.		0	0.0	0	0	0.0	Amt. retained for liquidity reserve /reserve months
16.	674,169	604,594		113,293	78,160		Carryforward used to reduce current assessment
D. Operational and Other Fixed Costs							
17.	137,231	117,851		35,246	60,505		Total administrative budget (from sheet b.)
18.	17,852	636	0.01%	4,585	303	0.01%	Bad debt allowance
19.	155,083	118,487		39,831	60,808		Sub-total anticipated operating costs
20.	892,604	0	0.00%	229,249	0	0.00%	Working capital reserve build-up
21.	0	0	0.00%	0	0	0.00%	Risk reserves
22.	\$ 1,047,687	\$ 118,487		\$ 269,080	\$ 60,808		Total fixed costs
E. Assessment Calculation							
23.	\$ 8,862,687	\$6,482,298		\$ 2,216,363	\$3,095,737		Total assessment funds needed (Row 10+ Row 22)
24.	\$ (674,169)	-\$604,594		\$ (113,293)	-\$78,160		Plus carry forward credit
25.	\$ 8,188,518	\$5,877,704		\$ 2,103,070	\$3,017,576		Net assessment funds needed
F. Per Assessable Covered Life Assessment							
26.	\$143.36	\$97.80		\$5.92	\$8.64		Annual assessment per covered life
27.	\$11.95	\$8.15		\$0.50	\$0.72		Monthly assessment per covered life calculated
28.	\$11.95	\$8.15		\$0.50	\$0.72		Monthly assessment per covered life recommended
G. Unexpended Assessments							
29.	910,456	636		233,834	303		² Unexpended assessments
H. Various Performance Metrics							
30.	2.00%	1.92%		2.15%	2.07%		VVPP operational costs as % of vaccine costs
31.	4.76%	5.63%		4.92%	5.78%		Lines 8 + 19 as % of vaccines
32.	11.37%	-31.80%		-13.79%	44.00%		% year to year change in assessment rate
33.	\$ 10.47	\$8.98	⁴	\$0.40	\$0.74		³ "Normalized" assessment rate (w/o lines 9, 14, & 20)
I. Vaccine Cost per Covered Life determination							
34.	\$ 9.84	\$ 8.50		\$ 0.38	\$ 0.70		Vaccine cost calculated
35.	\$ 9.84	\$ 8.50		\$ 0.38	\$ 0.70		Vaccine cost recommended

Notes:

- ¹ The provision for cost increases is applied for 9 months for childhood vaccines and 6 months for adult vaccines in developing the line 01. cost estimates. (This is due to the respective contract change dates, i.e. 4/1 for childhood vaccines and 7/1 for adult vaccines.)
- ² Carryforward cash amounts, if any, will be used for a working capital reserve if needed, and then applied to reduce future assessments unless otherwise directed by VDH.
- ³ This rate assumes that the working capital reserve is adequate and so included no reserves and also no carry forward.

**Vermont Vaccine Purchasing Program
Budget Estimates and Allocations**

Line ↓	Column →	A	B	C	D	E	F	G	H
				CHILDREN				ADULT	
		Prior Year	Unallocated ¹	Specific	Allocated ¹	Total	Specific	Allocated ¹	Total
01.	Administrative Fees (KidsVax®)								
02.	Annual Base Fee	167,977	173,856 ²		114,878	114,878		58,978	58,978
03.	Expense Allowance (travel)		- ⁵		-	-		-	-
04.	Other	-	-	-	-	-	-	-	-
05.	Subtotal	167,977	173,856	-	114,878	114,878	-	58,978	58,978
	General Expenses								
06.	Bank Fees & Service Charges	4,500	4,500 ³		2,973	2,973		1,527	1,527
07.	Auditing Fees				-	-		-	-
08.	Legal Fees				-	-		-	-
09.	VVPP Miscellaneous Expenses				-	-		-	-
10.	Office Expense				-	-		-	-
11.	Telephone Expense				-	-		-	-
12.	Postage and Shipping Expense				-	-		-	-
13.	Significant Website Enhancement				-	-		-	-
14.	Public Information Expense (other than web site)				-	-		-	-
15.	Insurance Expense (D&O)				-	-		-	-
16.	Printing Expense				-	-		-	-
17.	Publications				-	-		-	-
18.	Travel Expense				-	-		-	-
19.	Meeting Expense				-	-		-	-
29.	Subtotal	4,500	4,500 ⁵	-	2,973	2,973	-	1,527	1,527
	Special Projects								
31.					-	-		-	-
32.					-	-		-	-
33.					-	-		-	-
39.	Subtotal				-	-		-	-
49.	Total Expenses	<u>172,477</u>	<u>178,356</u>	<u>-</u>	<u>117,851</u>	<u>117,851</u>	<u>-</u>	<u>60,505</u>	<u>60,505</u>
59.	Budgeted for Bad Debt								

NOTES:

¹ "Unallocated" in this spreadsheet means that the specific item is not specific to either child or adult vaccines. If no other rule is given, allocation will be based upon the ratio of the child & adult total vaccine costs, plus VDH administrative fees (tab a. line 10), plus any carry forward credit or debit (tab a. line 16), respectively, to the total. That computation is as follows:

total child:	5,759,217	total adult:	2,956,768	66.08%	is the child % of total
--------------	-----------	--------------	-----------	--------	-------------------------

² Comprehensive fee for 2017 as agreed after VVPP RFP process in 2016.

³ Allowing for implementation of lockbox if approved by State of VT.

⁴ Actual costs, if any. Presently expected to be zero.

⁵ Bundled in KidsVax comprehensive fee for normal amounts.

⁶ To be set as part of the assessment work.

Prior Year's Financial Recap

Column →	A	B	C
Line ↓			
Revenues			
01.	Carryforward from prior year	\$0.00	
02.	VVPP assessment collections over federal fiscal year	\$10,194,574.84	
03.	317 grant funds received	\$330,766.12	
04.	VFC (including VFC flu)	\$7,565,216.33	
05.	TRICARE settlement ¹	\$785,867.00	
06.	Payment made during the period but due from	\$77,216.09	
07.	prior period)		
08.			
09.			\$18,953,640.38
Expenditures / Allowances			
10.	State bulk purchase	\$7,319,193.30	
11.	State Flu	\$431,547.60	
12.	State direct ship	\$1,187,290.60	
13.	VFC (including VFC flu) vaccine purchases	\$7,565,216.33	
14.	KidsVax ²	\$167,977.00	
15.	VDH administration fee	\$212,335.00	
16.	Year 3 of 3 of initial cash amortization	\$1,056,559.94	
17.	317 program vaccine purchases	\$330,766.12	
18.			<u>-\$18,270,885.89</u>
19.	Vaccine Fund Carryforward ³ (applied to reduce this year's assessment)		<u>\$682,754.49</u>
		<u>Child</u>	<u>Adult</u>
20.	No cash amortization ⁴	\$0.00	\$0.00

Notes:

¹ Initial settlement amount offered by Tricare, final settlement may be higher.

² Full amount of KidsVax contract through 12/31/2017.

³ Excess of revenues (including prior carryforward) over expenditures.

⁴ The stipulated recovery amount was payable over 3 years (see 2015 Assessment Setting worksheet). 2017 was the last year of this amortization.

VT DOH Pediatric Vaccine Purchase Estimates
Federal Fiscal Year

Column →
Line ↓

	A	B	C	D	E	F	G	H	I
	Vaccine	Brand Name	NDC	Prior Year Cost Per Dose	Prior Year Actual Doses Distributed	Prior Year Actual Cost	VVPP Cost Per Dose ¹	Total Estimated Doses	Total Estimated Cost
01.	DTaP	Daptacel	49281-0286-10	\$16.73	450	\$7,572	\$17.16	960	\$16,474
02.		Infanrix	58160-0810-11	\$16.85	6,150	\$106,268	\$17.73	6,550	\$116,132
03.	DTaP-HepB-IPV	Pediarix	58160-0811-52	\$54.90	12,840	\$714,708	\$56.43	13,340	\$752,776
04.	DTaP-IPV/Hib	Pentacel	49281-0510-05	\$56.91	4,475	\$254,284	\$56.738	6,520	\$369,932
05.	DTaP-IPV	Kinrix	58160-0812-11	\$39.57	6,430	\$254,435	\$39.57	5,310	\$210,117
06.		QuadraCel	49281-0562-10	N/A	0	\$0	\$39.57	1,640	\$64,895
07.	Hib	ActHIB	49281-0545-05	\$9.55	18,525	\$176,914	\$9.55	19,375	\$185,031
08.		PedvaxHIB	00006-4897-00	\$12.48	0	\$0	\$12.79	0	\$0
09.		Hiberix	58160-0818-11	\$9.46	\$0	\$0	\$9.46	0	\$0
10.	HepA	Vaqta	00006-4831-41	\$18.23	0	\$0	\$18.75	0	\$0
11.		Havrix	58160-0825-11	\$17.83	20,890	\$381,810	\$18.68	21,000	\$392,280
12.	HepB	Recombivax	00006-4981-00	\$12.30	0	\$0	\$12.30	0	\$0
13.		Engerix B	58160-0820-52	\$11.60	7,230	\$85,114	\$12.30	9,140	\$112,422
14.	HepA-HepB	Twinrix	58160-0815-52	\$56.97	10	\$570	\$56.97	0	\$0
15.	HPV	(HPV9) Gardasil	00006-4119-03	\$141.60	19,480	\$2,837,551	\$154.28	18,850	\$2,908,178
16.	IPV	IPOL	49281-0860-10	\$12.72	2,640	\$34,022	\$13.04	2,000	\$26,080
17.	Influenza	Fluzone – Quad	49281-0625-15	\$13.77	25,350	\$349,070	N/A	N/A	N/A
18.			49281-0516-25	\$19.143	16,000	\$306,288	N/A	N/A	N/A
19.			49281-0416-50	\$14.925	17,900	\$267,158	N/A	N/A	N/A
20.			49281-0416-10	\$15.818	4,550	\$71,972	N/A	N/A	N/A
21.		Fluarix - Quad	58160-0905-52	\$14.430	1,200	\$17,316	N/A	N/A	N/A
22.	Influenza	Fluzone – Quad	49281-0417-50	N/A	0	\$0	\$15.675	37,250	\$583,894
23.			49281-0517-25	N/A	0	\$0	\$15.675	14,450	\$226,504
24.		FluLaval	19515-0912-52	N/A	0	\$0	\$14.430	12,800	\$184,704
25.	MMR	MMR II	00006-4681-00	\$20.11	6,800	\$138,615	\$20.59	8,300	\$170,897
26.	MMRV	ProQuad	00006-4171-00	\$114.25	6,760	\$788,288	\$118.72	7,400	\$878,528
27.	MCV4	Menaetra	49281-0589-05	\$89.16	12,430	\$1,108,259	\$89.16	11,390	\$1,015,532
28.		Menveo	58160-0955-09	\$68.32	275	\$20,022	\$71.70	240	\$17,208
29.	MENB	Trumenba	00005-0100-10	\$95.75	0	\$0	\$100.98	0	\$0
30.		Bexsero	58160-0976-06	\$98.51	1,362	\$141,014	\$98.51	2,125	\$209,334
31.	PCV13	Prevnar 13	00005-1971-02	\$120.39	23,150	\$2,862,304	\$126.97	25,000	\$3,174,250
32.	PPSV23	Pneumovax 23	00006-4943-00	\$46.40	130	\$6,146	\$48.72	230	\$11,206
33.	RV	(RV5) RotaTeq	00006-4047-41	\$66.49	230	\$15,556	\$69.12	230	\$15,898
34.		(RV1) Rotarix	58160-0854-52	\$86.75	10,430	\$927,894	\$91.05	12,000	\$1,092,600
35.	Td	Tenivac	49281-0215-10	\$19.69	134	\$2,638	\$19.69	0	\$0
36.		Td Vaccine	13533-0131-01	\$13.20	476	\$6,039	\$12.513	745	\$9,322
37.	Tdap	Boostrix	58160-0842-11	\$31.37	8,120	\$255,038	\$31.37	4,200	\$131,754
38.		Adacel	49281-0400-10	\$31.37	1,170	\$36,509	\$30.99	5,000	\$154,950
39.	VAR	Varivax	00006-4827-00	\$88.34	7,290	\$660,555	\$92.72	8,000	\$741,760

40.	Totals:			242,877	\$12,833,924		254,045	\$13,772,656
41.					Adjusted for utilization Increase			\$13,774,033
42.					Further adjusted for price increase			\$14,135,601
43.			Dollars		%			
44.	VFC award		\$7,998,850		56.59%			-\$7,998,850

Notes:
¹ CDC pediatric vaccine contract purchase prices as of 9/1/17

**VT DOH Adult Vaccine Purchase Estimates
Federal Fiscal Year**

Column →
Line ↓

	A	B	C	D	E	F	G	H	I
	Vaccine	Brand Name	NDC	Prior Year Cost Per Dose	Prior Year Actual Doses Distributed	Prior Year Actual Cost	VVPP cost per dose ¹	Total Estimated Doses	Total Estimated Cost
01.	HepA	Vaqta	00006-4096-02	\$27.68	0	\$0	\$31.18	0	\$0
02.		Havrix	58160-0826-11	\$25.73	3,230	\$83,108	\$25.73	4,700	\$120,931
03.	HepB	Engerix B	58160-0821-52	\$25.33	3,970	\$104,114	\$29.38	4,810	\$141,318
04.	HepA-HepB	Twinrix	58160-0815-52	\$54.66	1,290	\$70,983	\$55.90	1,600	\$89,440
05.	HPV	(HPV9) Gardasil	00006-4119-03	\$119.04	1,400	\$163,328	\$116.22	2,520	\$292,874
06.	Influenza	Fluarix	58160-0907-52	\$12.72	400	\$5,088	\$12.72	400	\$5,088
07.	MMR	MMR II	00006-4681-00	\$40.00	110	\$4,527	\$42.12	505	\$21,271
08.	MCV4	Menactra	49281-0589-05	\$74.334	305	\$22,872	\$76.152	600	\$45,691
09.		Menveo	58160-0955-09	\$72.45	0	\$0	\$69.74	35	\$2,441
10.	MENB	Trumenba	00005-0100-10	\$85.54	0	\$0	\$82.22	0	\$0
11.		Bexsero	58160-0976-06	\$117.49	139	\$14,876	\$106.28	250	\$26,570
12.	PCV13	Prevnar 13	00005-1971-02	\$96.56	530	\$54,089	\$112.74	890	\$100,336
13.	PPSV23	Pneumovax 23	00006-4943-00	\$26.15	5,190	\$158,213	\$47.80	5,775	\$276,045
14.	Td	Tenivac	49281-0215-10	\$12.271	701	\$8,735	\$13.575	0	\$0
15.		Td Vaccine	13533-0131-01	\$13.20	3,698	\$47,951	\$13.575	6,620	\$89,867
16.	Tdap	Boostrix	58160-0842-11	\$24.39	13,940	\$339,669	\$24.36	14,000	\$341,040
17.		Adacel	49281-0400-10	\$23.724	2,940	\$70,532	\$24.769	3,000	\$74,307
18.	VAR	Varivax	00006-4827-00	\$66.36	40	\$2,690	\$69.94	50	\$3,497
19.	Zoster	Shingrix (HZ/su)*	58160-0823-11	N/A	0	\$0	\$105.00	14,500	\$1,522,500
20.		Zostavax (ZVL)	00006-4963-41	\$117.12	5,310	\$643,207	\$134.16	600	\$80,496
21.	Weighted Average						\$53.14		
22.	Totals:				43,193	\$1,793,982		60,855	\$3,233,711
23.					Adjusted for utilization increase				\$3,249,880
24.					Further adjusted for price increase				\$3,306,753
25.						Dollars	%		
					Estimated 317 Funding	\$380,110	11.49%		-\$380,110

¹ CDC adult vaccine contract purchase prices as of 9/1/17

*Shingrix cost unavailable, estimated at 75% of private cost